- Home
- BNTC vs MNPR Comparison
BNTC vs MNPR Comparison
Compare BNTC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- MNPR
- Stock Information
- Founded
- BNTC 1995
- MNPR 2014
- Country
- BNTC United States
- MNPR United States
- Employees
- BNTC N/A
- MNPR N/A
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- BNTC Health Care
- MNPR Health Care
- Exchange
- BNTC Nasdaq
- MNPR Nasdaq
- Market Cap
- BNTC 88.1M
- MNPR 95.5M
- IPO Year
- BNTC N/A
- MNPR 2019
- Fundamental
- Price
- BNTC $10.68
- MNPR $18.09
- Analyst Decision
- BNTC Strong Buy
- MNPR Strong Buy
- Analyst Count
- BNTC 5
- MNPR 3
- Target Price
- BNTC $22.60
- MNPR $27.33
- AVG Volume (30 Days)
- BNTC 33.8K
- MNPR 1.5M
- Earning Date
- BNTC 11-14-2024
- MNPR 11-08-2024
- Dividend Yield
- BNTC N/A
- MNPR N/A
- EPS Growth
- BNTC N/A
- MNPR N/A
- EPS
- BNTC N/A
- MNPR N/A
- Revenue
- BNTC N/A
- MNPR N/A
- Revenue This Year
- BNTC N/A
- MNPR N/A
- Revenue Next Year
- BNTC N/A
- MNPR N/A
- P/E Ratio
- BNTC N/A
- MNPR N/A
- Revenue Growth
- BNTC N/A
- MNPR N/A
- 52 Week Low
- BNTC $2.69
- MNPR $1.37
- 52 Week High
- BNTC $12.89
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- BNTC 53.25
- MNPR 60.19
- Support Level
- BNTC $10.25
- MNPR $16.26
- Resistance Level
- BNTC $10.89
- MNPR $19.70
- Average True Range (ATR)
- BNTC 0.43
- MNPR 2.15
- MACD
- BNTC -0.07
- MNPR -0.07
- Stochastic Oscillator
- BNTC 69.39
- MNPR 74.36
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.